ENGOT-EN9/LEAP-001: A PHASE 3 STUDY OF FIRST-LINE PEMBROLIZUMAB PLUS LENVATINIB COMPARED WITH CHEMOTHERAPY IN ADVANCED OR RECURRENT ENDOMETRIAL CANCER

Randall, L.Marth, C.Vulsteke, C.Rubio, M. JesusMakker, V.Braicu, I.McNeish, I.Madry, R.Ayhan, A.Hasegawa, K.Wu, X.Dutta, L.Xu, C.Keefe, S.Lee, J.Pignata, S.2021-03-192021-03-1920201048-891Xhttp://hdl.handle.net/11727/5566enginfo:eu-repo/semantics/closedAccessENGOT-EN9/LEAP-001: A PHASE 3 STUDY OF FIRST-LINE PEMBROLIZUMAB PLUS LENVATINIB COMPARED WITH CHEMOTHERAPY IN ADVANCED OR RECURRENT ENDOMETRIAL CANCERConference Object30A130A130000616549600276